OncoMatch/Clinical Trials/NCT04951947
JS-201 Combined With Lenvatinib in the Treatment of Small-cell Lung Cancer
Is NCT04951947 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies JS201 combine with Lenvatinib for small-cell lung cancer.
Treatment: JS201 combine with Lenvatinib — This is a prospective, single-arm phase II clinical study to evaluate the efficacy and safety of JS-201 combined with lenvatinib in the treatment of small-cell lung cancer that has failed previous chemotherapy combined with PD-L1. The primary observational endpoint is ORR, and the secondary observational endpoint is PFS, OS. The intervention mode is JS201 300mg i.v Q2w, lenvatinib 8mg po. Qd.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Cancer type
Small Cell Lung Cancer
Disease stage
Required: Stage IV
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Must have received: EC plus anti-PD-L1 therapy — first-line
The patient failed first-line EC+PD-L1 treatment
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT04951947 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received EC plus anti-PD-L1 therapy.
What disease stage is eligible?
Stage IV is required.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages